NeuroOne Medical Technologies (NMTC) said Tuesday it has regained compliance with Nasdaq's minimum share price requirement for continued listing.
The company said it was notified by Nasdaq Monday that its bid price deficiency had been cured and NeuroOne was in compliance will all applicable listing standards.
Shares of the company were down 2.2% in recent trading.
Price: 1.06, Change: -0.02, Percent Change: -2.22